Matthew W. Foehr - Feb 15, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
President and COO
Signature
By: Charles S. Berkman For: Matthew W. Foehr
Stock symbol
LGND
Transactions as of
Feb 15, 2022
Transactions value $
-$438,569
Form type
4
Date filed
2/16/2022, 07:24 PM
Previous filing
Jan 28, 2022
Next filing
May 3, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Tax liability -$153K -1.23K -0.71% $123.68 173K Feb 15, 2022 Direct F1
transaction LGND Common Stock Tax liability -$151K -1.22K -0.71% $123.68 172K Feb 15, 2022 Direct F2
transaction LGND Common Stock Tax liability -$135K -1.09K -0.63% $123.68 171K Feb 15, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019.
F2 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020.
F3 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/03/2021.